OncoSil Medical
ASX:OSLSydney, Australia· Est.
OncoSil delivers Ph‑radioactive brachytherapy for pancreatic cancer using ultrasound‑guided Ph‑32 microparticle implants.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
OncoSil delivers Ph‑radioactive brachytherapy for pancreatic cancer using ultrasound‑guided Ph‑32 microparticle implants.
Oncology
Technology Platform
Targeted intratumoural brachytherapy using Phosphorous‑32 microparticles delivered via endoscopic ultrasound‑guided injection.
Opportunities
Successful Phase 2 results could enable rapid market entry in a high‑unmet‑need oncology segment and provide a platform to expand P‑32 brachytherapy to other solid tumours.
Risk Factors
Clinical trial outcomes, regulatory approval pathways, and reimbursement acceptance for a novel brachytherapy device are the primary risks.
Competitive Landscape
OncoSil competes with conventional radiation therapy, I‑125 seed brachytherapy, and emerging ablative technologies; its differentiation lies in the use of short‑half‑life P‑32 microparticles delivered minimally invasively under EUS guidance.